Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo
暂无分享,去创建一个
T. Furmark | M. Fredrikson | M. Bergström | B. Långström | F. Åhs | E. Pich | K. Wahlstedt | L. Appel | M. Bani | Eva Jacobsson | Åsa Michelgård | S. Zancan | K. Flyckt | M. Grohp | L. Nilsson | E. M. Pich
[1] J. Lorberbaum,et al. Neural correlates of speech anticipatory anxiety in generalized social phobia , 2004, Neuroreport.
[2] Claude Nahmias,et al. A PET provocation study of generalized social phobia , 2004, Psychiatry Research: Neuroimaging.
[3] Mats Fredrikson,et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia , 2004, Neuroscience Letters.
[4] S. Preskorn,et al. Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression , 2004, Neuropsychopharmacology.
[5] G. Klerman,et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale , 1992, Social Psychiatry and Psychiatric Epidemiology.
[6] G. Bentley,et al. Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608 , 2003, Neuropharmacology.
[7] M. Liebowitz,et al. Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder , 2003, Psychological Medicine.
[8] R. Adolphs. Cognitive neuroscience: Cognitive neuroscience of human social behaviour , 2003, Nature Reviews Neuroscience.
[9] T. Furmark,et al. Cerebral blood flow during anticipation of public speaking in social phobia: a PET study , 2002, Biological Psychiatry.
[10] M. Raichle,et al. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.
[11] J. Gorman,et al. Molecular targets in the treatment of anxiety , 2002, Biological Psychiatry.
[12] Gregory G. Brown,et al. Increased amygdala activation to angry and contemptuous faces in generalized social phobia. , 2002, Archives of general psychiatry.
[13] R. V. Van Heertum,et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652 , 2002, Psychopharmacology.
[14] J. Lachowicz,et al. The Gerbil Elevated Plus-maze II: Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists , 2002, Neuropsychopharmacology.
[15] Michael Erb,et al. Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans , 2002, Neuroscience Letters.
[16] M. Egan,et al. Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.
[17] F. Graeff. On serotonin and experimental anxiety , 2002, Psychopharmacology.
[18] S. Hofmann,et al. The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. , 2002, Behaviour research and therapy.
[19] D. Clark,et al. Patients with generalized social phobia direct their attention away from faces. , 2002, Behaviour research and therapy.
[20] R. L. Ribeiro,et al. Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[21] T. Furmark,et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. , 2002, Archives of general psychiatry.
[22] T. Furmark,et al. Social phobia: overview of community surveys , 2002, Acta psychiatrica Scandinavica.
[23] David G. Amaral,et al. The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety , 2002, Biological Psychiatry.
[24] Dan J Stein,et al. Functional brain imaging and pharmacotherapy in trichotillomania Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[25] R. Gomeni,et al. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. , 2002, Nuclear medicine and biology.
[26] M. Mintun,et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study , 2001, Biological Psychiatry.
[27] H Fischer,et al. Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. , 2001, The American journal of psychiatry.
[28] I. Holme,et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia , 2001, British Journal of Psychiatry.
[29] M. Keller,et al. An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. , 2001, Psychiatric services.
[30] R. Hen,et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] Michael Davis,et al. The amygdala: vigilance and emotion , 2001, Molecular Psychiatry.
[32] Joseph E LeDoux. Emotion circuits in the brain. , 2009, Annual review of neuroscience.
[33] D. Nutt,et al. The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology. , 2000, Pharmacology & therapeutics.
[34] N. Kalin,et al. Emotion, plasticity, context, and regulation: perspectives from affective neuroscience. , 2000, Psychological bulletin.
[35] P. Jerabek,et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.
[36] R. Schwarting,et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery , 2000, Neuropeptides.
[37] P. Farvolden,et al. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI , 2000, Expert opinion on investigational drugs.
[38] S. Stahl,et al. Serotonin and anxiety: current models , 2000, International clinical psychopharmacology.
[39] S. File. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats , 2000, Psychopharmacology.
[40] J L Lancaster,et al. Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.
[41] Dan J Stein,et al. Functional brain imaging and pharmacotherapy in social phobia: Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram , 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[42] J M Gorman,et al. Neuroanatomical hypothesis of panic disorder, revised. , 2000, The American journal of psychiatry.
[43] M. Liebowitz,et al. Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study , 1999, European Psychiatry.
[44] Dan J Stein,et al. Social anxiety disorder , 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[45] M S Kramer,et al. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.
[46] T. Furmark,et al. Social phobia in the general population: prevalence and sociodemographic profile , 1999, Social Psychiatry and Psychiatric Epidemiology.
[47] R. Maddock. The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain , 1999, Trends in Neurosciences.
[48] P. Farvolden,et al. Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia , 1999 .
[49] G. Griebel,et al. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? , 1999, Pharmacology & therapeutics.
[50] Wolfgang Grodd,et al. Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia , 1999, Biological Psychiatry.
[51] B. Lerer,et al. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers , 1999, Psychopharmacology.
[52] J. Gorman,et al. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. , 1999, The Journal of clinical psychiatry.
[53] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[54] U Klose,et al. fMRI reveals amygdala activation to human faces in social phobics , 1998, Neuroreport.
[55] S. Paradiso. The Emotional Brain: The Mysterious Underpinnings of Emotional Life , 1998 .
[56] R. Mattick,et al. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. , 1998, Behaviour research and therapy.
[57] T. Hergueta,et al. The mini international neuropsychiatric interview , 1998, European Psychiatry.
[58] J. Davidson. Pharmacotherapy of social anxiety disorder. , 1998, The Journal of clinical psychiatry.
[59] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[60] S. File. Anxiolytic Action of a Neurokinin1 Receptor Antagonist in the Social Interaction Test , 1997, Pharmacology Biochemistry and Behavior.
[61] E. Courchesne,et al. Attentional Activation of the Cerebellum Independent of Motor Involvement , 1997, Science.
[62] E. Hollander,et al. The neuroanatomy of 5-HT dysregulation and panic disorder. , 1997, The Journal of neuropsychiatry and clinical neurosciences.
[63] Kiyohisa Takahashi,et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat , 1996, Brain Research.
[64] M. Brandão,et al. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test , 1996, Physiology & Behavior.
[65] J. Calixto,et al. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. , 1996, European journal of pharmacology.
[66] Daniel S. O'Leary,et al. Sample Size and Statistical Power in [15O]H2O Studies of Human Cognition , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[67] Gavin Kilpatrick,et al. GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity , 1996, Regulatory Peptides.
[68] Joseph E LeDoux. The emotional brain , 1996 .
[69] J. Gray,et al. The neuropsychology of anxiety: reprise. , 1996, Nebraska Symposium on Motivation. Nebraska Symposium on Motivation.
[70] E. Lindström,et al. Axis V—Global Assessment of Functioning Scale , 1994, Acta psychiatrica Scandinavica.
[71] M. Koch,et al. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats , 1994, Behavioural Brain Research.
[72] E. Brodin,et al. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions , 1994, Neuropeptides.
[73] Karl J. Friston,et al. Statistical parametric maps in functional imaging: A general linear approach , 1994 .
[74] R. Hales,et al. J Neuropsychiatry Clin Neurosci , 1992 .
[75] A. Ganong,et al. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. , 1991, Science.
[76] M. Torrens. Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .
[77] Lars R. Bergman,et al. EXACON: A Fortran 77 Program for the Exact Analysis of Single Cells in a Contingency Table , 1987 .
[78] J. Gray,et al. The neuropsychology of anxiety. , 1985, Issues in mental health nursing.
[79] C. Spielberger,et al. Manual for the State-Trait Anxiety Inventory , 1970 .
[80] R. Hunter. Book Review: Post-Operative Cardiac Care , 1966 .